Thermo Fisher Scientific (TMO) Projected to Post Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 23rd. Analysts expect Thermo Fisher Scientific to post earnings of $5.22 per share and revenue of $10.68 billion for the quarter. Thermo Fisher Scientific has set its FY 2025 guidance at 21.760-22.840 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business's revenue was up .2% on a year-over-year basis. During the same quarter last year, the business earned $5.11 EPS. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Trading Up 1.3%

Shares of Thermo Fisher Scientific stock traded up $5.56 during trading on Thursday, hitting $421.87. The stock had a trading volume of 1,280,944 shares, compared to its average volume of 2,009,831. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $627.88. The firm's fifty day simple moving average is $409.84 and its 200-day simple moving average is $474.37. The stock has a market cap of $159.25 billion, a PE ratio of 24.73, a PEG ratio of 2.22 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.41%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on TMO shares. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Argus dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a research report on Tuesday, June 24th. Finally, Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $600.30.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Thermo Fisher Scientific stock. Brighton Jones LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 28.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,409 shares of the medical research company's stock after acquiring an additional 988 shares during the period. Brighton Jones LLC's holdings in Thermo Fisher Scientific were worth $2,293,000 at the end of the most recent quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.